Open AccessA Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
Author(s) -
Donald C. Moore,
Daniel Thompson
Publication year - 2021
Publication title -
journal of the advanced practitioner in oncology
Language(s) - English
Resource type - Journals
eISSN - 2150-0886
pISSN - 2150-0878
DOI - 10.6004/jadpro.2021.12.4.8
Subject(s) - bruton's tyrosine kinase , ibrutinib , medicine , chronic lymphocytic leukemia , mantle cell lymphoma , cancer research , b cell , tyrosine kinase , lymphoma , pharmacology , leukemia , immunology , receptor , antibody
The B-cell receptor signaling pathway plays an integral role in the proliferation and survival of malignant B cells. Targeting the B-cell receptor pathway via the inhibition of Bruton tyrosine kinase (BTK) has evolved the treatment of a variety of B-cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenström macroglobulinemia. Currently, there are three BTK inhibitors approved by the U.S. Food and Drug Administration: ibrutinib, acalabrutinib, and zanubrutinib. This article reviews the pharmacology, clinical efficacy, safety, dosing, drug-drug interactions, and implications for advanced practitioners of BTK inhibitors in the treatment of B-cell malignancies.